APVO insider John Niederhuber receives 7,200 RSU award, 1-year vest

Rhea-AI Filing Summary

Aptevo Therapeutics director John Niederhuber was reported to have acquired 7,200 restricted stock units (RSUs) on 08/06/2025. Each RSU converts one-for-one into common stock, and the transaction is recorded as an acquisition at a $0 price, indicating no cash was paid for the award. The filing shows the resulting beneficial interest as 7,200 RSUs held in a direct ownership form.

The RSUs are described to vest in full on the first anniversary of the grant, at which point they will convert into 7,200 common shares if the vesting conditions are satisfied. The Form 4 is filed by a single reporting person and contains only this equity award; it does not provide information on total outstanding shares or percentage ownership, so the document alone does not quantify dilution or ownership percentage.

Positive

• 7,200 RSUs granted with explicit one-for-one conversion to common stock, providing clear share equivalence.
• Vesting in full on the first anniversary gives a defined timetable for when RSUs convert to shares.
• Reported as acquisition at $0 price, indicating the award was granted without cash payment.

Negative

• None.

Insights

Compensation Analyst

TL;DR: Director received a routine 7,200 RSU award vesting in one year; filing lacks share-count context to judge materiality.

The filing documents a standard equity-based compensation award: 7,200 RSUs convertible 1-for-1 to common stock, reported as an acquisition with a $0 price, and vesting in full one year after grant. From a compensation-structure perspective, the disclosure is complete regarding grant size and vesting timetable, but the Form 4 does not include outstanding share counts or percentages, so this single data point cannot determine potential dilution or material impact on shareholder value.

Corporate Governance Expert

TL;DR: Routine director equity grant; clear vesting schedule disclosed, but filing provides no context on ownership percentage or governance impact.

The document shows a director-level equity award intended to vest after one year, with ownership recorded as direct. It discloses the mechanics (1-for-1 conversion, vesting date, and acquisition code) required for transparency under Section 16 reporting. The filing does not show additional transactions, related-party terms, or any restrictions beyond the stated vesting, and it does not provide metrics needed to assess whether the grant is unusually large for governance or shareholder considerations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Niederhuber John

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2025		A		7,200		(2)	(2)	Common Stock	7,200	$0	7,200	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. The RSUs vest in full on the first anniversary of the date of grant.

	/s/ SoYoung Kwon, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did APVO insider John Niederhuber acquire?

He acquired 7,200 restricted stock units (RSUs) that convert one-for-one into Aptevo common stock.

When do the RSUs vest for APVO (APVO)?

The RSUs vest in full on the first anniversary of the grant date.

Was any cash paid for the RSU award?

No; the transaction is reported at a $0 price, indicating no cash consideration was paid.

How are the RSUs reported on the Form 4?

They are listed as derivative securities acquired (Transaction Code A), with 7,200 derivative securities beneficially owned following the transaction and ownership held directly.

Does the Form 4 show Niederhuber's percentage ownership of APVO?

No; the filing discloses the number of RSUs but does not provide total outstanding shares or percentage ownership.

Was this filing made by multiple reporting persons?

No; the Form indicates it was filed by one reporting person.